Methylphenidate is increasingly portrayed not only as a treatment for attention-deficit hyperactivity disorder (ADHD) but also, misleadingly, as a drug that ‘improves concentration’ or as a ‘study drug’, a framing that has become increasingly visible across social media and news coverage. In Japan, news reports have highlighted social media posts suggesting non-medical use of methylphenidate among students preparing for entrance examinations. ¹ Similar concerns have been reported in South Korea, particularly with respect to the College Scholastic Ability Test, with ADHD medications reportedly being misused for the purpose of improving academic performance. ²

This phenomenon may reflect competitive pressures surrounding academic achievement and entrance examinations, together with a discourse that frames medication as a means of performance enhancement. Non-medical use of prescription stimulants for studying or examination preparation has repeatedly been documented. One systematic review found that 16–29% of students with stimulant prescriptions had been asked to give, sell or trade their medication to others. ^{Reference Wilens, Adler, Adams, Sgambati, Rotrosen and Sawtelle3} More recently, a 2025 systematic review and meta-analysis of individuals prescribed stimulant medication for ADHD estimated the average prevalence of past-year misuse to be 22.6% and that of past-year diversion to be 18.2%. ^{Reference Forrest, Chen and Jagadheesan4}

Social media may play an important part in disseminating such narratives. On platforms such as TikTok and X, ADHD may be reduced to everyday experiences that many people encounter, such as difficulty concentrating, procrastination or an untidy room. A cross-sectional study of the 100 most popular ADHD-related videos on TikTok classified 52% as misleading and only 21% as useful. ^{Reference Yeung, Ng and Abi-Jaoude5} Videos based on personal experiences also attracted particularly high levels of engagement. ^{Reference Yeung, Ng and Abi-Jaoude5} By presenting common experiences as though they were disorder-specific symptoms, such an information environment may shape help-seeking behaviour, expectations of diagnosis and, ultimately, demand for medication.

The COVID-19 pandemic offers an important lesson in this regard. The World Health Organization described the information environment surrounding COVID-19 as an ‘infodemic’ – an overabundance of information, some accurate and some not, that made it difficult for people to identify trustworthy sources and reliable guidance. ^{Reference Cinelli, Quattrociocchi, Galeazzi, Valensise, Brugnoli and Schmidt6} Research on COVID-19 showed that patterns of misinformation dissemination varied across platforms, and that the diffusion patterns of information from reliable and questionable sources were not always clearly distinguishable. ^{Reference Cinelli, Quattrociocchi, Galeazzi, Valensise, Brugnoli and Schmidt6} In other words, misinformation may spread not only in the form of conspicuous ‘fake news’ but also by becoming embedded within ordinary flows of information.

ADHD medications face an analogous risk. When personal accounts claiming that ‘the medication helped me concentrate’ or posts implying routes of non-medical acquisition become highly visible on social media, they may generate exaggerated expectations regarding the medication’s effects and reduce psychological barriers to illicit or non-medical access. Although such accounts may truthfully describe the poster’s subjective experience, they often omit whether an ADHD diagnosis was clinically established, as well as information on dosage, adverse effects, co-occurring conditions and objective academic outcomes. Such experiences therefore cannot establish the general effectiveness or safety of the medication.

A practical lesson from the COVID-19 pandemic is that correcting misinformation after it has spread is unlikely to be sufficient. Psychological inoculation, or ‘prebunking’, uses brief videos to teach people in advance about manipulation techniques commonly used in misinformation. This approach has been shown to improve recognition of manipulative content, ability to distinguish trustworthy from untrustworthy information, and the quality of decisions about sharing information. ^{Reference Roozenbeek, Van Der Linden, Goldberg, Rathje and Lewandowsky7} For ADHD medications, clinicians should therefore address why ‘study drug’ narratives are persuasive rather than relying on simple denial. Two distinctions matter. Self-identification with ADHD traits may support self-understanding and help-seeking, but prescribing and formal academic accommodations should be based on an individualised assessment of functional impairment, not symptoms alone. Likewise, prescription stimulants may have modest cognitive effects in healthy people, but this does not make non-medical use a safe or equitable form of academic support. ^{Reference Ilieva, Hook and Farah8}

These considerations also show why the focus should extend beyond methylphenidate. Although the reports discussed here concern methylphenidate, Australian research has examined non-medical academic use of several stimulants, including methylphenidate and dextroamphetamine. ^{Reference Lucke, Jensen, Dunn, Chan, Forlini and Kaye9} The relevant target for prevention is therefore the broader narrative that prescription stimulants are tools for academic competition, rather than any single drug. Clinician-led communication should acknowledge the narrative’s appeal, distinguish self-identification from clinical evaluation, clarify that modest cognitive effects do not make non-medical use safe or legitimate, and explain how non-medical use and diversion may restrict access for patients with a clinical need. These messages should be communicated pre-emptively in brief, accessible and repeatable formats. Appropriate prescribing cannot be protected in the consultation room alone. Clinicians must act as guardians of diagnostic quality and as public communicators addressing digitally generated demand for prescription stimulants.